Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Assets (2016 - 2025)

Enanta Pharmaceuticals' Current Assets history spans 14 years, with the latest figure at $198.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 25.9% year-over-year to $198.7 million; the TTM value through Dec 2025 reached $198.7 million, down 25.9%, while the annual FY2025 figure was $204.3 million, 31.85% down from the prior year.
  • Current Assets reached $198.7 million in Q4 2025 per ENTA's latest filing, down from $204.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $448.5 million in Q2 2023 to a low of $198.7 million in Q4 2025.
  • Average Current Assets over 5 years is $312.6 million, with a median of $312.4 million recorded in 2022.
  • Peak YoY movement for Current Assets: soared 43.26% in 2023, then tumbled 36.1% in 2024.
  • A 5-year view of Current Assets shows it stood at $327.0 million in 2021, then fell by 13.23% to $283.7 million in 2022, then surged by 37.57% to $390.3 million in 2023, then plummeted by 31.3% to $268.1 million in 2024, then decreased by 25.9% to $198.7 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Current Assets are $198.7 million (Q4 2025), $204.3 million (Q3 2025), and $222.7 million (Q2 2025).